These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Venous thromboembolism in patients receiving multimodality therapy for thoracic malignancies. Patel A; Anraku M; Darling GE; Shepherd FA; Pierre AF; Waddell TK; Keshavjee S; de Perrot M J Thorac Cardiovasc Surg; 2009 Oct; 138(4):843-8. PubMed ID: 19660355 [TBL] [Abstract][Full Text] [Related]
24. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Connolly GC; Khorana AA Thromb Res; 2010 Apr; 125 Suppl 2():S1-7. PubMed ID: 20433985 [TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. Vemulapalli S; Chintala L; Tsimberidou AM; Dhillon N; Lei X; Hong D; Kurzrock R Am J Hematol; 2009 Jul; 84(7):408-13. PubMed ID: 19437507 [TBL] [Abstract][Full Text] [Related]
26. Cancer in males and risk of venous thromboembolism. Beyer-Westendorf J; Werth S; Halbritter K; Weiss N Thromb Res; 2010 Apr; 125 Suppl 2():S155-9. PubMed ID: 20433997 [TBL] [Abstract][Full Text] [Related]
28. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Trujillo-Santos J; Nieto JA; Tiberio G; Piccioli A; Di Micco P; Prandoni P; Monreal M; Thromb Haemost; 2008 Sep; 100(3):435-9. PubMed ID: 18766259 [TBL] [Abstract][Full Text] [Related]
29. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Trujillo-Santos J; Di Micco P; Iannuzzo M; Lecumberri R; Guijarro R; Madridano O; Monreal M; Thromb Haemost; 2008 Nov; 100(5):905-11. PubMed ID: 18989537 [TBL] [Abstract][Full Text] [Related]
30. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels. Folkeringa N; Coppens M; Veeger NJ; Bom VJ; Middeldorp S; Hamulyak K; Prins MH; Büller HR; van der Meer J Thromb Haemost; 2008 Jul; 100(1):38-44. PubMed ID: 18612536 [TBL] [Abstract][Full Text] [Related]
31. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Khorana AA; Francis CW; Culakova E; Kuderer NM; Lyman GH Cancer; 2007 Nov; 110(10):2339-46. PubMed ID: 17918266 [TBL] [Abstract][Full Text] [Related]